Terfenadine
General information:
| Withdrawn ID: | w42 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | R06AX12 |
| Molecular Formula: | C32H41NO2 |
| Molweight: | 471.673 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | Yes |
|---|---|
| First approved: | 1985 |
| First death: | 1991 |
| First withdrawn: | 1997 |
| Last withdrawn: | 1997 |
| Reference: | https://www.ncbi.nlm.nih.gov/pubmed/24697004 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Terfenadine as primary suspect: | 1 |
|---|
Reported final outcomes:
| Life-Threatening condition: | 1 |
|---|
Reported side-effects:
| Side-effect | Case number |
|---|---|
| TORSADE DE POINTES | 1 |
| LOSS OF CONSCIOUSNESS | 1 |
| DRUG INTERACTION | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| P00352 | 0.7 | Retinal dehydrogenase 1 | AL1A1_HUMAN |
| P02545 | 1000 | Prelamin-A/C | LMNA_HUMAN |
| P10636 | 112.2 | Microtubule-associated protein tau | TAU_HUMAN |
| P35367 | 1 | Histamine H1 receptor | HRH1_HUMAN |
| P40225 | 2511.9 | Thrombopoietin | TPO_HUMAN |
| P42345 | 7362.1 | Serine/threonine-protein kinase mTOR | MTOR_HUMAN |
| P42858 | 3162.3 | Huntingtin | HD_HUMAN |
| P51589 | 8100 | Cytochrome P450 2J2 | CP2J2_HUMAN |
| Q12809 | 22 | Potassium voltage-gated channel subfamily H member 2 | KCNH2_HUMAN |
| Q13936 | 1320 | Voltage-dependent L-type calcium channel subunit alpha-1C | CAC1C_HUMAN |
| Q14524 | 971 | Sodium channel protein type 5 subunit alpha | SCN5A_HUMAN |
Toxicity information:
| Toxicity class: | 4 |
|---|---|
| Toxicity type: | cardiovascular |
| LD50: | 650 mg/kg |
External links:
| ChEBML: | CHEMBL17157 |
|---|---|
| DrugBank: | DB00342 |